Citations 4

Medically ready for discharge: A multisite “point‐in‐time” assessment of hospitalized patients

Journal of Hospital Medicine | August 9, 2023 | Volume: 18 | Issue: 9 | Pages: 795-802

10.1002/jhm.13184 | PMID 37553979

Abstract Background Time spent awaiting discharge after the acute need for hospitalization has resolved is an important potential contributor to hospital length of stay (LOS). Objective To measure the prevalence, impact, and context of patients who remain hospitalized for prolonged periods after completion of acute care needs. Design, Setting, and Participants We conducted a cross‐sectional “point‐in‐time” survey at each of 15 academic US hospitals using a structured data collection tool with on‐service acute care medicine attending physicians in fall 2022. Main Outcomes and Measures Primary outcomes were number and percentage of patients considered “medically ready for discharge” with emphasis on those who had experienced a “major barrier to discharge” (medically ready for discharge for ≥1 week). Estimated LOS attributable to major discharge barriers, contributory discharge needs, and associated hospital characteristics were measured. Results Of 1928 patients sampled, 35.0% ( n = 674) were medically ready for discharge including 9.8% ( n = 189) with major discharge barriers. Many patients with major discharge barriers (44.4%; 84/189) had spent a month or longer medically ready for discharge and commonly (84.1%; 159/189) required some form of skilled therapy or daily living support services for discharge. Higher proportions of patients experiencing major discharge barriers were found in public versus private, nonprofit hospitals (12.0% vs. 7.2%; p = .001) and county versus noncounty hospitals (14.5% vs. 8.8%; p = .002). Conclusions Patients experience major discharge barriers in many US hospitals and spend prolonged time awaiting discharge, often for support needs that may be outside of clinician control.
P2‐347: BRI2 (ITM2B) inhibits Aβ deposition

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2008.05.1424

P2‐338: Substrate‐targeting gamma‐secretase modulators

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2008.05.1415

P4–289: Mechanistic insights into the in vitro and in vivo modulation of Aβ42 levels and amyloid pathology by NSAIDS and related compounds

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_20 | Pages: No page available

10.1016/j.jalz.2006.05.2028